This clinical trial aims to generate a CAR-EGFR-TGFβR-knockout T by deleting TGF-receptor II using CRISPR/Cas9, to study its anti-tumour activity and safety profiles in EGFR-positive advanced unresectable or metastatic biliary tract cancer, previously treated. Here, EGFR is linked to biliary tract cancer.